Review

The Art and Science of Thyroid Surgery in the Age of Genomics: 100 years after Theodor Kocher
  • Seza Gulec
Mol Imaging Radionucl Ther 2017; 26: 1-9 DOI: 10.4274/2017.26.suppl.01 PMID:28117284
18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Other Thyroid Cancers: Medullary, Anaplastic, Lymphoma and So Forth
  • Mine Araz
  • Derya Çayır
Mol Imaging Radionucl Ther 2017; 26: 1-8 DOI: 10.4274/mirt.60783 PMID:28291004
Lymph Node Dissection for Differentiated Thyroid Cancer
  • Aviram Mizrachi
  • Ashok R. Shaha
Mol Imaging Radionucl Ther 2017; 26: 10-15 DOI: 10.4274/2017.26.suppl.02 PMID:28117285
Radioactive Iodine Remnant Ablation: The Beta-knife Completion Thyroidectomy
  • Seza Gulec
  • Russ Kuker
Mol Imaging Radionucl Ther 2017; 26: 16-23 DOI: 10.4274/2017.26.suppl.03 PMID:28117286
Genomic Profiling of Thyroid Nodules: Current Role for ThyroSeq Next-Generation Sequencing on Clinical Decision-Making
  • Atil Y. Kargi
  • Marcela Perez Bustamante
  • Seza Gulec
Mol Imaging Radionucl Ther 2017; 26: 24-35 DOI: 10.4274/2017.26.suppl.04 PMID:28117287
Nuclear Medicine in Thyroid Diseases in Pediatric and Adolescent Patients
  • Bilge Volkan-Salancı
  • Pınar Özgen Kıratlı
Mol Imaging Radionucl Ther 2015; 24: 47-59 DOI: 10.4274/mirt.76476 PMID:26316469
Nuclear Molecular and Theranostic Imaging for Differentiated Thyroid Cancer
  • Arif Sheikh
  • Berna Polack
  • Yvette Rodriguez
  • Russ Kuker
Mol Imaging Radionucl Ther 2017; 26: 50-65 DOI: 10.4274/2017.26.suppl.06 PMID:28117289
I-124 Imaging and Dosimetry
  • Russ Kuker
  • Manuel Sztejnberg
  • Seza Gulec
Mol Imaging Radionucl Ther 2017; 26: 66-73 DOI: 10.4274/2017.26.suppl.07 PMID:28117290
Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer
  • Steven M. Larson
  • Joseph R. Osborne
  • Ravinder K. Grewal
  • R. Michael Tuttle
Mol Imaging Radionucl Ther 2017; 26: 80-86 DOI: 10.4274/2017.26.suppl.09 PMID:28117292
Thyroid Stimulating Hormone Receptor
  • Murat Tuncel
Mol Imaging Radionucl Ther 2017; 26: 87-91 DOI: 10.4274/2017.26.suppl.10 PMID:28117293
The Thyroid Na+/I- Symporter: Molecular Characterization and Genomic Regulation
  • Hani Alotaibi
  • Merve Tuzlakoğlu-Öztürk
  • Uygar Halis Tazebay
Mol Imaging Radionucl Ther 2017; 26: 92-101 DOI: 10.4274/2017.26.suppl.11 PMID:28117294
A Concise Atlas of Thyroid Cancer Next-Generation Sequencing Panel ThyroSeq v.2
  • Jorge Alsina
  • Raul Alsina
  • Seza Gulec
Mol Imaging Radionucl Ther 2017; 26: 102-117 DOI: 10.4274/2017.26.suppl.12 PMID:28117295

Case Report

Concurrent Endometrial Carcinosarcoma and Thyroid Papillary Carcinoma: PET CT Imaging Findings
  • Mine Genc
  • Berhan Genc
  • Serap Karaarslan
  • Secil Kurtulmus
  • Seyhan Yalaz
  • Inanc Karapolat
Mol Imaging Radionucl Ther 2015; 24: 34-37 DOI: 10.4274/mirt.96268
Ectopic Pelvic Kidney Mimicking Sacral Metastasis on Post-Therapy Iodine-131 Scan of a Thyroid Cancer Patient
  • Selin Soyluoğlu Demir
  • Gül Ege Aktaş
  • Ahmet Polat
  • Ali Sarıkaya
Mol Imaging Radionucl Ther 2017; 26: 43-46 DOI: 10.4274/mirt.75436 PMID:28291010
I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy
  • Stephan Probst
  • Gad Abikhzer
  • Guillaume Chaussé
  • Michael Tamilia
Mol Imaging Radionucl Ther 2018; 27: 84-87 DOI: 10.4274/mirt.59454 PMID:29889031
Unexpected Uptake by the Gallbladder in Post-Ablative I-131 Scan
  • Kemal Ünal
  • Özgür Ümit Akdemir
Mol Imaging Radionucl Ther 2015; 24: 85-86 DOI: 10.4274/mirt.57441 PMID:26316474

Case Reports

Is Every Patient Followed up as a Papillary Thyroid Cancer Patient Really That?
  • Ummuhan Abdulrezzak
  • Ahmet Tutus
  • Mustafa Kula
  • Figen Öztürk
  • Işın Soyuer
Mol Imaging Radionucl Ther 2012; 21: 38-41 DOI: 10.4274/Mirt.022866 PMID:23487501

Original Research

Prognostic Value of Basal Serum Thyroglobulin Levels, but Not Basal Antithyroglobulin Antibody (TgAb) Levels, in Patients with Differentiated Thyroid Cancer
  • Isa Neshandar Asli
  • Ali Shafiepour Siahkali
  • Babak Shafie
  • Hamid Javadi
  • Majid Assadi
Mol Imaging Radionucl Ther 2014; 23: 54-59 DOI: 10.4274/mirt.39200 PMID:24963446
Is Very High Thyroid Stimulating Hormone Level Required in Differentiated Thyroid Cancer for Ablation Success?
  • Zekiye Hasbek
  • Bülent Turgut
Mol Imaging Radionucl Ther 2016; 25: 79-84 DOI: 10.4274/mirt.88598 PMID:27277324
The Effect of High Dose Radioiodine Therapy on Formation of Radiation Retinopathy During Thyroid Cancer Treatment
  • Tülay Kaçar Güveli
  • Sezer Özkan
  • Müge Öner Tamam
  • Ercan Uyanık
  • Nurcan Ediz
  • Mehmet Mülazımoğlu
  • Tevfik Özpaçacı
Mol Imaging Radionucl Ther 2014; 23: 84-88 DOI: 10.4274/mirt.33042 PMID:25541931
Recurrence Incidence in Differentiated Thyroid Cancers and the Importance of Diagnostic Iodine-131 Scintigraphy in Clinical Follow-up
  • Filiz Hatipoğlu
  • İnanç Karapolat
  • Özgür Ömür
  • Ayşegül Akgün
  • Ahmet Yanarateş
  • Kamil Kumanlıoğlu
Mol Imaging Radionucl Ther 2016; 25: 85-90 DOI: 10.4274/mirt.35220 PMID:27277325
The Evaluation of Microcarcinoma in Differentiated Thyroid Cancers According to Old and New TNM Classification
  • Zekiye Hasbek
  • Bülent Turgut
  • Taner Erselcan
  • Ayhan Koyuncu
  • Mehmet Fatih Börksüz
  • Nergiz Hacer Turgut
  • Fadime Yumuk
Mol Imaging Radionucl Ther 2011; 20: 94-99 DOI: 10.4274/MIRT.13 PMID:23486990

About Journal

Forms

Useful Links

Applications